Other

Merck Sharp + Dohme Corp.

Millennium Pharmaceuticals Limited

The University of Texas System

Bristol-myers Squibb Compnay

Mark David Ayers

Terrill K McClanahan

Michael V Nebozhyn

Andrey Loboda

Jared K Lunceford

Robert C Bast

Erin E Murphy

Edwin A Clark

Andrew I Damokosh

Jeffrey L Brown

Gabriel N Hortobagyi

Lajos Pusztai

Natalia Iartchouk

W Fraser Symmans

Heather Hirsch

Kenneth R Hess

Terrance Golden

John A Hynak

Jim Stec

Jared Lunceford

Terrill K Mcclanahan

A gene expression platform, which is a combination of a set of genes that are correlated with response to a PD-1 antagonist in multiple tumor types and a normalization gene set, is disclosed. A method and system of using the gene expression platform to derive gene signature biomarkers of anti-tumor response to a PD-1 antagonist and to test patient samples for predictive gene signature biomarkers are also disclosed.

System and methods for deriving gene signature biomarkers of response to PD-1 antagonists

The present disclosure describes baseline and on treatment blood-based gene signature biomarkers that are predictive of tumor sensitivity to therapy with a PD-1 antagonist. The on-treatment biomarkers comprise a PD-L1 gene signature or an interferon gamma gene signature and the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The disclosure also provides methods and kits for testing tumor samples for these biomarkers, as well as methods for treating subjects with a PD-1 antagonist based on the test results.

Blood-based biomarkers of tumor sensitivity to PD-1 antagonists

A reloadable magazine apparatus that accepts two or more cartridges that enables users to quickly load a plurality of cartridges into the magazine through a loading window, for use in a firearm. Embodiments of the invention enable a user to place a clip of cartridges directly in the magazine, for example a stripper clip, and rapidly load the magazine. Embodiments of the invention enable the magazine to be configured for use in capacity and removable magazine restricted states through the incorporation of ammunition stops and locking tabs.

Reloadable magazine apparatus configured to accept a plurality of cartridges

The present invention may be used in systems for non-volatile memory storage of electronic data. A first substrate member may have a first and second surface with a first and second substrate connector spaced apart and attached to the first surface and a first and second spacer element spaced apart and attached to said second surface. A NAND flash controller device may be mounted on the first surface and connected to the substrate connectors and spacer elements. Multiple NAND memory devices may be mounted on the second surface and be connected to the NAND flash controller device. A second substrate member may have a first and second surface with multiple NAND flash memory devices mounted on at least one of the surfaces. The second substrate member may be attached to the spacer elements on the first surface and said multiple NAND flash memory devices may be connected to the NAND flash controller device.

Non-volatile memory module

VEGFR-2 biomarkers useful in a method for identifying and monitoring a mammal that will respond therapeutically to a method of treating cancer comprising administering an VEGFR-2 modulator, wherein the method comprises (a) exposing the mammal to the VEGFR-2 modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the VEGFR-2 modulator indicates that the mammal will respond therapeutically to the method of treating cancer and (c) wherein the level of the biomarker in a mammal after exposure to a VEGFR-2 modulator indicates that the mammal has responded therapeutically to the method of treating cancer.

Methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators by measuring the level of collagen type IV

The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer.

Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer

A continuous throttle regulation device employs a motor throttle body located proximate to a motor or engine, and an accelerator pedal located remote from the motor or engine. A return switch (RS) is responsive to the motor throttle body, and a pressure sensitive switch (PSS) is responsive to the accelerator pedal position. Power is passed through both switches then to a critical electronic element required to run the motor, such as a distributor. Therefore, when both switches are open, power to the critical element is interrupted, slowing or stopping the motor. When both switches are closed, the power is restored to the ignition causing the motor to operate. Therefore, the system may engage and disengage automatically and intermittently numerous times in a short period of time, thereby safely limiting motor speed, while restoring power in a split second to keep the motor running and operational. This technology may also be applied to gasoline, diesel, and electric motors to regulate their operation.

Continuous throttle regulation device

The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of 'sensitivity markers.' These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of 'resistance markers.' These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent.

Compositions and methods for the identification, assessment, prevention, and therapy of human cancers

Growing community of inventors

Pennington, NJ, United States of America

Mark David Ayers